Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have an order in. Does anyone know when the last trade was?
Something is going on here. .000001 to .01 then .009 and holding.
Small trades, around $500. total.
But why ?
I wouldn't buy in, probably couldn't any way, but my ancient holdings have gone from a total loss to a gain . Can't sell at the moment, no volume , but who knows what is to come?
So since CA--(Marketwired - Jun 14, 2017) - Eco Petroleum Solutions, Inc. (OTC PINK: ECPO) announces that it has completed the acquisition of Immb. What happened to the IMMB stock?? What happened to ECPO?? Harry screwed everything up once again??!! Your Nothing but a pirate Harry Zhibalov!! Your no difference than Bo Linton!
Anyone know what the status of IMMB shareholders
is or will be?
is the ratio 1 to 1 stock swap with ECPO
what is this saying about IMMB stock as far as the merger,CAN IMMB SHARES BE purchased now ,,,JOKER
On March 9, 2017, the Company (ECPO) entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock, of Immunotech for 60,000,000 shares of the Company’s Series A preferred stock. The current shareholders of Immunotech ownership, not less than 80% of the issued and outstanding shares of ECPO common stock at any given time. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Immunotech’s 200 Million outstanding Series B Preferred convert one to one but do have a voting preference and shall be exchanged for 200 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Series B outstanding will be included in the 80% calculation for the Newly Created Preferred.
================================
All this and no 8K?
Thanks Bro. These guys burn tickers like marshmallows at a cub scout bon fire.
Lmao looks like they found the rat it's now taking over the ECPO shell.
What's up with this company?!! Making all these great test results but yet can't get this thing trading?!!
Are you referring to the one where they used six rats and the one healthy rat ran away before anyone could verify the results?
True story I read on he Bulgarian web. You can't make this stuff up. LOL
weres blane i just he calls me
Thanks for sharing your feelings.
I too have feelings, however, feelings are often based on emotions and and can vary from day to day or mood to mood.
I suppose feelings are also used in making stock decisions, again, not very reliable or factual, but nevertheless, we all have them from time to time.
GLTU
$BSSP
Haha how lame......
Can you come to the BSSP board and let us know what was in this IMMB IPF video? It is touted several times per day. Seems very few have seen it as it had been taken down.
Guess this rumor was wrong
Moving forward? I don't get it.. why was he held back at IMMB?
thank you, good morning.
no clue as I am not following this...GLTY if you are still holding
hi my friend/ still ah sleeper ????? IMMB
not interested in money or milestone payments ????? IMMB
If Harry was to give up position then yes somebody with the right sense has a lot of work to do to clean it up. However Harry had the right biomedical research team that specializes in clinical trials to go thru the FDA process but Harry chose never to go to the meetings. SynteractHCR.
so good product but mgmt'ing bad ????? immb
if he gives up position , is it ah ?????
i will read/ usually finra sec take steps.
immb
Doesn't matter how many shells you put him in if he's running it he will burn it to the ground. He's already been warned by other attorneys about jumping into another shell with the IPF Patent. Could open up a whole bunch of issues from IMMB share holders
Exactly! He is a good guy but does not know how to run a company.
so an entry into another shell ????? wondering how good ????? IMMB
so good doc but no common sense ????? i like the reads.IMMB
Yes it's a very interesting product. However Harry Zhabilov has no business running a public company! He needs to focus his energy in the lab. If he would stop trying to control things he would have already been in US FDA! He scared investors off
interesting product/ 'Immunotech Laboratories, Inc. (IMMB)'
And because Zhabilov has already had IMMB suspended by the SEC it will also render BSSP useless in the eyes of the SEC.
Immunotech Laborator (IMMB)
0.001 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
- - - - -
IMMB Detailed Quote Wiki
i think some reviewing should be done/ IMMB
Uldic was an empty shell in Zimbabwe owned by one of Zhabilov's Bulgarian friends who had extensive business contacts in Africa. If the PR would have read that IMMB was working with a person instead of the shell (which would be in fact the exact same PR) then IMMB would still be trading.
Zhabilov got hosed by the SEC imo.
website still live/ http://www.immunotechlab.com/
PETITION OF IMMUNOTECH LABORATORIES, INC.
FOR TERMINATION OF TRADING SUSPENSION
http://www.immunotechlab.com/sec-filings/
Welcome to Immunotech Laboratories
This drug development company is committed to the commercialization of our proprietary proteins for the treatment of debilitating infectious diseases and for the better health of mankind.
IPF_microscopeAfter decades of research, we determined that it was time to take Immunotech Laboratories, Inc. and our product to the next level. Therefore, we are glad to inform you that Immunotech Laboratories, Inc. is currently trading publicly under the ticker symbol of IMMB (Pink Sheets / OTC.NASDAQ Exchange).
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS and Hepatitis C and to modulate the immune system.
IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INF-?, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to HIV infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to reduce viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML via CMTX - Tue Oct 21, 7:03AM CDT
http://www.barchart.com/headlines/story/2982355/immunotech-laboratories-inc-enters-into-agreement-to-market-potential-ebola-virus-disease-evd-treatment-and-implement-strategy-for-company-s-itv-1-infectious-diseases-treatment-in-africa
Monrovia, California (FSCwire) - Immunotech Laboratories, Inc. (OTC PINK: IMMB) (“Immunotech” or the “Company”) and wholly-owned subsidiary Immunotech Laboratories,
BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus,
and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa
With the establishment of an African operation, Immunotech hopes to fulfill the Company's vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus.
In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company’s new agreement with Uldic.
ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus. IPF is a platform technology that can be used to facilitate a broad range of applications.
It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today.
IPF has not shown itself to be subject to viral resistance, and it is cost effective.
The Company says that the immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens.
CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.
Immunotech has isolated IPF which is the most extensively studied CD 56 ligand to date. The compounds has their ability to stimulate human NKT-cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor.
A lead compound, IPF, emerged from these studies and this protein exhibits a stronger adjuvant effect in various HIV vaccine platforms in mice. IPF also provides a protective adjuvant effect with a candidate HIV and HCV vaccine.
While the majority of the Company’s studies have focused on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat infectious diseases.
About Immunotech Laboratories, Inc.
Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
The Company strives to become a leader in immuno-therapeutic treatment and the prevention of HIV/AIDS, Cancer and other immuno-related disorders.
For more information visit: http://www.immunotechlab.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact:
Billy Ray: 770-910-5380
Immunotech Laboratories, Inc.
Phone: 818-409-8988
Email: ir@immunotechlab.com
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/immunotech10212014.pdf
Source: Immunotech Laboratories Inc. (OTC Pink:IMMB) http://www.immunotechlab.com/
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2014 Filing Services Canada Inc.
Copyright (C) 2014 Filing Services Canada Inc.
http://www.barchart.com/headlines/story/2982355/immunotech-laboratories-inc-enters-into-agreement-to-market-potential-ebola-virus-disease-evd-treatment-and-implement-strategy-for-company-s-itv-1-infectious-diseases-treatment-in-africa
Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML via CMTX - Thu Oct 09, 7:45AM CDT
http://www.barchart.com/headlines/story/2748300/immunotech-laboratories-inc-enters-into-negotiations-with-uldic-investment-pvt-ltd-for-market-development
Monrovia, California (FSCwire) - Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc.(the “Company”)
and Immunotech Laboratories, BG (IMMB-BG”) the Company announced
today that they have entered into negotiations with
Uldic Investment Pvt. Ltd. (“Uldic” or the “Representative/Distributor”), located in Zimbabwe,
to pursue the development of market opportunities and Clinical Testing for the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) in Africa,
initially focusing on clinical testing for Hepatitis C in Mauritius Island and Malawi.
About Immunotech Laboratories, Inc.
Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immuno related disorders.
For more information visit:
http://www.immunotechlab.com Safe Harbor Statement:
This news release contains forward-looking statements that involve
risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development,
regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC.
IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable,
any of the assumptions could be inaccurate,
including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition,
the development of studies and strategies leading to commercialization of IPF in the United States,
the obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all,
and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
In light of the significant uncertainties inherent in the forward-looking statements included herein,
Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard
the forward-looking statements as a representation.
Contact:
Immunotech Laboratories, Inc,
818-409-8988
ir@immunotechlab.com
GIC
813-213-8156
Houston, Texas
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/immunotech10092014.pdf
Source: Immunotech Laboratories Inc. (OTC Pink:IMMB) http://www.immunotechlab.com/
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2014 Filing Services Canada Inc.
Copyright (C) 2014 Filing Services Canada Inc.
i am reading. does look like good pr.
Latest Immunotech Laborator (IMMB) Headlines
http://www.barchart.com/news/IMMB
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML - Tue Oct 21, 7:03AM CDT
(full story)
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease ("EVD") Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
BusinessWire - Tue Oct 21, 7:00AM CDT
Immunotech Laboratories, Inc. (OTC PINK: IMMB) ("Immunotech" or the "Company") and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa. (full story)
Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML - Thu Oct 09, 7:45AM CDT
(full story)
I read the SEC final ruling and it was BS imo.
so good to trade ????? Immunotech Laboratories, Inc. (IMMB)'
do you know SS here ????? 'Immunotech Laboratories, Inc. (IMMB)'
Followers
|
65
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2447
|
Created
|
02/04/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |